Low-density lipoprotein

Video Library

  • Video Library

    Therapeutic Management of Dyslipidaemia

    In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the therapeutic management of dyslipidaemia. Dyslipidaemia, a key risk factor for cardiovascular diseases, is conventionally managed through therapies targeting lipoproteins such as LDL, Lp(a), IDL + VLDL through small-molecule therapeutics. Despite their effectiveness, off-target events and poor patient compliance often pose significant challenges. Hence novel therapeutics, such as small interfering RNAs, antisense oligonucleotides, and monoclonal antibodies have been developed. These advancements highlight a significant step forward in the management of dyslipidaemia. Prof. Cannon emphasizes these main points in the video, aiming to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.

    View

  • Running time: 35 minutes, 49 seconds

     

    00.16 Lp(a) structure and metabolism

    01.51 Elevated Lp(a) prevalence and risk of cardiovascular diseases

    02.38 Factors influencing Lp(a) level

    03.35 Physiological functions of Lp(a)

    04.12 Atherogenicity of Lp(a)

    04.56 Clinical implication of Lp(a) elevation

    05.25 Genetic variants associated with increased Lp(a) concentrations

    05.44 Association between high Lp(a) level and risk of various cardiovascular diseases

    07.43 Clinical implication of Lp(a) elevation at low LDL-C

    08.47 Lp(a) categories increases absolute baseline risk of traditional risk factors

    09.40 Is reducing Lp(a) physiologically safe?

    10.34 Strategies to lower Lp(a) level

    11.57 Future directions in Lp(a) research

    12.37 Summary

    Video Library

    Lp(a):What is it and its role in atherosclerosis

    In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.

    View
View All Low-density lipoprotein Video Library

Infographics

View All Low-density lipoprotein Infographics

Articles

View All Low-density lipoprotein Articles

Case Studies

  • Case Studies

    August 2023

    Take this short quiz to test your knowledge on the recently published debate on dyslipidemias titled “Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers”.

    CLICK HERE TO VIEW THE DEBATE.

    Eur Heart J. 2023 Jul 1;44(25):2292-2304. doi: 10.1093/eurheartj/ehad275

    Take

  • Case Studies

    Quiz of the month – April 2023

    Take our patient case study quiz specially curated for you by our Faculty Member, Prof. Samer Ellahham.

    Case Study: A 65-year-old man with a history of dyslipidemia, type 2 diabetes mellitus and systemic hypertension.

     

    Presentation:

    New onset crescendo angina x 5 days culminating

    Rest pain for the past 2h

    No history of other vascular events or heart attack, no TIA or stroke

    Weight: 90 kg

    Exam: BP 150/85 (slightly elevated), Heart Rate 80

    No murmur detected

     

    Medication:

    Valsartan 160 mg daily, Aspirin 81 mg daily, Rosuvastatin 10 mg daily, Metformin 500 mg twice daily

     

    Labs:

    BMI 31kg/m2, waist circumference 101.6 cm (40 inches), (-) tobacco (quit last year – 60-pack-year history)

    Normal CBC, electrolytes

    Troponin: Elevated

    Electrocardiogram:1-2 mm horizontal ST depression infero-lateral leads

    Chest X-ray: Normal

     

    Lipid panel:

    Total cholesterol (TC) 192 mg/dL

    HDL-C 46 mg/dL

    Triglycerides 180 mg/dL (non-fasting)

    LDL-C 110 mg/dL

    Non-HDL-C 146 mg/ dL

     

    What are the first impressions about this patient?

    Take

  • Case Studies

    Case Study – December 2022

    Our patient case study specially curated for you by our Faculty Member, Prof. Samer Ellahham on concerns about statin associated Diabetes Mellitus.

    Case Study: RS is a 64-year-old Male having dyslipidemia.

     

    Vital parameters:

    BP 144/87 mm Hg

    Low-density lipoprotein cholesterol (LDL-C) 112 mg/dL

    High-density lipoprotein cholesterol (HDL-C) of 47 mg/dL

    Triglycerides 190 mg/dL

    (-) tobacco, (-) alcohol

    Body mass index (BMI) 33 kg/m2

     

    Medication:

    Valsartan 80 mg/d

     

    Family history:

    Father developed type 2 diabetes mellitus (T2DM) and ASCVD at age 58

     

    Labs:

    Fasting blood glucose 103 mg/dL

    HbA1C 5.8%

    Serum Creatinine 1.1 mg/dL

    Urinary analysis within normal limits

     

     

    RS reports that he is reluctant to take statins as they cause diabetes especially with his family history.

    Read More
View All Low-density lipoprotein Case Studies